Capricor Therapeutics, Inc. (CAPR)

USD 12.52

(-5.15%)

Market Cap (In USD)

569.28 Million

Revenue (In USD)

25.17 Million

Net Income (In USD)

-22.28 Million

Avg. Volume

1.56 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.52-23.4
PE
-
EPS
-
Beta Value
4.016
ISIN
US14070B3096
CUSIP
14070B309
CIK
1133869
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Linda Marbán Ph.D.
Employee Count
-
Website
https://www.capricor.com
Ipo Date
2007-02-13
Details
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.